Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)

OBJECTIVES: The choice of drug treatment in advanced soft tissue sarcoma (STS) continues to be a challenge regarding efficacy, quality of life (QoL) and toxicity. Unlike other cancer types, where integrating patient-reported outcomes (PRO) has proven to be beneficial for QoL, there is no such eviden...

Descripción completa

Detalles Bibliográficos
Autores principales: Hentschel, Leopold, Richter, Stephan, Kopp, Hans-Georg, Kasper, Bernd, Kunitz, Annegret, Grünwald, Viktor, Kessler, Torsten, Chemnitz, Jens Marcus, Pelzer, Uwe, Schuler, Ulrich, Freitag, Janet, Schilling, Andrea, Hornemann, Beate, Arndt, Karin, Bornhäuser, Martin, Schuler, Markus Kajo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Palliative Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454199/
https://www.ncbi.nlm.nih.gov/pubmed/32859662
http://dx.doi.org/10.1136/bmjopen-2019-035546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454199/
https://www.ncbi.nlm.nih.gov/pubmed/32859662
http://dx.doi.org/10.1136/bmjopen-2019-035546

Ejemplares similares